PUBLIC COMPANY
save$FOLDAMICUS THERAPEUTICS, INC.
$FOLD14.490.00%Princeton, NJ, USupdated 12d ago
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
community read0 votes
pipeline
4
marketed
3
phase 3
1
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 33Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
- phase3A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
- —A Study of Patients With Fabry Disease (US Specific)
- —A Global Prospective Observational Registry of Patients With Pompe Disease
- phase3A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
- phase3Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
- —A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
- phase3A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 2, 26SELLCampbell Bradley L· President and CEO−$323K↗
🐶 Hiring Signal
News
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 7h ago
- The China Debate: Biotech deserves a deeper discussionFor the last few months, I've been watching the debate about the US-China biotech rivalry unfold, and I've been unsatisfied. There are great, smart people arguing about the future of the biotech in…endpoints · 7d ago
- ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whileBiogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.fiercebiotech · 13d ago
- FDA approves Freenome colorectal cancer blood test to be marketed by AbbottThe FDA has approved Freenome’s new blood-based colorectal cancer test, SimpleScreen CRC, which Abbott will exclusively market in the U.S.fiercebiotech · 15d ago
- Opinion: STAT readers on the value of primary care, obesity as a disease, and more“The real opportunity is to move beyond policies and narratives that pit specialties against one another,” presidents of the AAFP, ACP, and AAP write.stat · 24d ago
- Nobel Laureate Jennifer Doudna enters AI protein design arenaJennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene-editing, is dipping her toes into a new, buzzy field: AI-powered pro…fiercebiotech · 27d ago
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.biopharma_dive · 2mo ago
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.biopharma_dive · 2mo ago
- Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech, wh…endpoints · 3mo ago
- Odyssey, on second try, snags $279M in an IPOAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…biopharma_dive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that